Ferroptosis mechanisms and its novel potential therapeutic targets for DLBCL

• DOI: 10.1016/j.biopha.2024.116386
• Publication Date: 2024-03-16T01:19:35Z
• Authors: Wenxia Bian; Haoran Li; Yuhan Chen; Yanhua Yu; Guojie Lei; Xinyi Yang; Sainan Li; Xi Chen; Huanjuan Li; Jing Yang; Chen Yang; Yanchun Li; Yi Zhou
• Keywords: 0301 basic medicine; 03 medical and health sciences

Diffuse large B-cell lymphoma (DLBCL), a heterogeneous lymphoid malignancy, poses significant threat to human health. The standard therapeutic regimen for patients with DLBCL is rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), typical cure rate of 50–70%. However, some either relapse after complete remission (CR) or exhibit resistance R-CHOP treatment. Therefore, novel approaches are imperative managing high-risk refractory DLBCL. Ferroptosis driven by iron-dependent phospholipid peroxidation, process that relies on the transition metal iron, reactive oxygen species (ROS), phospholipids containing polyunsaturated fatty acids-containing (PUFA-PLs). Research indicates ferroptosis implicated in various carcinogenic anticancer pathways. Several hematological disorders heightened sensitivity cell death induced ferroptosis. cells, particular, demonstrate an increased demand iron upregulation expression acid synthase. Additionally, there exists correlation between ferroptosis-associated genes prognosis may be promising target therapy. In this review, we elucidate mechanisms, its role DLBCL, potential targets This review offers insights into application treatment strategies